Related Experiment Videos
[Dangerous side effects of lithium therapy].
Psychiatrie, Neurologie Und Medizinische Psychologie. Beihefte
|January 1, 1977
Summary
Combined lithium and haloperidol therapy can cause pharmacogenic delirium. Lithium may also induce diabetes insipidus and hydrocephalus, particularly in elderly patients or those with prior brain injury.
Area of Science:
- Neuroscience
- Pharmacology
- Endocrinology
Background:
- Lithium is a common mood stabilizer, often used in combination with antipsychotics like haloperidol.
- Potential adverse effects of lithium and haloperidol monotherapy are well-documented.
- The synergistic effects and combined risks of this specific therapeutic combination require further investigation.
Observation:
- Two cases of pharmacogenic delirium were observed following combined lithium-haloperidol treatment.
- One case of lithium-induced nephrogenic diabetes insipidus with secondary hypertension was reported.
- Development of hydrocephalus internus male-resorptivus was also associated with lithium therapy in one patient.
Findings:
- Patients in all reported cases had potential predisposing factors such as advanced age or previous cerebral injury.
- The study discusses the potentiating effects of lithium and haloperidol on synaptic transmission.
- A fundamental mechanism for lithium's therapeutic actions and side effects is proposed, involving Na-K stimulated ATPase, active transport, and adenylcyclase.
Implications:
- This report highlights the potential for severe adverse events when lithium and haloperidol are combined.
- Understanding the underlying mechanisms involving Na-K ATPase and adenylcyclase is crucial for managing lithium therapy.
- Clinicians should carefully consider patient disposition and monitor for these specific side effects during combined treatment.